R\u016fst valuace VR LIFE, siln\u00e1 klinick\u00e1 trakce a p\u0159ipravovan\u00fd vstup na americk\u00fd trh posiluj\u00ed strategii H2 Global Group. Inovativn\u00ed platforma, kter\u00e1 kombinuje japonsk\u00fd v\u00fdzkum molekul\u00e1rn\u00edho vod\u00edku a virtu\u00e1ln\u00ed realitu, nav\u00edc zaznamen\u00e1v\u00e1 rostouc\u00ed z\u00e1jem ze strany arm\u00e1dy i slo\u017eek integrovan\u00e9ho z\u00e1chrann\u00e9ho syst\u00e9mu.<\/p>\n\n\n\n
Evropsk\u00fd MedTech inov\u00e1tor H2 Global Group zrychluje svou expanzi do Spojen\u00fdch st\u00e1t\u016f a na glob\u00e1ln\u00ed trhy prost\u0159ednictv\u00edm portfoliov\u00e9 spole\u010dnosti VR LIFE. Ta ned\u00e1vno uzav\u0159ela seedov\u00e9 kolo financov\u00e1n\u00ed, kter\u00e9 v\u00edce ne\u017e zdvojn\u00e1sobilo hodnotu pod\u00edlu H2 Global Group. V \u010dervnu 2023 z\u00edskala dce\u0159in\u00e1 spole\u010dnost H2 Investment 20% pod\u00edl ve VR LIFE za p\u0159ibli\u017en\u011b 630.000 USD. V \u00fanoru 2026 uzav\u0159ela VR LIFE seedov\u00e9 kolo ve v\u00fd\u0161i 650.000 USD podpo\u0159en\u00e9 institucion\u00e1ln\u00edmi investory, \u010d\u00edm\u017e implikovan\u00e1 hodnota z\u0159ed\u011bn\u00e9ho 18,26% pod\u00edlu H2 Investment vzrostla na p\u0159ibli\u017en\u011b 1,38 milionu USD. Tento miln\u00edk posiluje pozici skupiny pro z\u00edsk\u00e1n\u00ed v\u011bt\u0161\u00edho pod\u00edlu na glob\u00e1ln\u00edm trhu zdravotnick\u00fdch prost\u0159edk\u016f, z n\u011bho\u017e USA tvo\u0159\u00ed 46 %, a sou\u010dasn\u011b roz\u0161i\u0159uje mezin\u00e1rodn\u00ed distribu\u010dn\u00ed s\u00ed\u0165.<\/p>\n\n\n\n
\"Budujeme vertik\u00e1ln\u011b integrovan\u00fd MedTech ekosyst\u00e9m, kter\u00fd spojuje pr\u016flomovou japonskou v\u011bdu, evropskou klinickou validaci a glob\u00e1ln\u00ed kapit\u00e1l k \u0159e\u0161en\u00ed t\u011bch nejnal\u00e9hav\u011bj\u0161\u00edch zdravotnick\u00fdch v\u00fdzev na\u0161\u00ed doby,\"\u00a0uvedl David Mar\u0161\u00e1lek, CEO a zakladatel H2 Global Group.\u00a0\"Otev\u00edr\u00e1me dve\u0159e americk\u00fdm, evropsk\u00fdm a glob\u00e1ln\u00edm investor\u016fm, partner\u016fm a distributor\u016fm, kte\u0159\u00ed rozpozn\u00e1vaj\u00ed tento struktur\u00e1ln\u00ed posun a cht\u011bj\u00ed z n\u011bj t\u011b\u017eit.\"<\/p>\n\n\n\n
Japonsk\u00e1 v\u011bda, patenty a prvn\u00ed H2 zdravotnick\u00fd prost\u0159edek na sv\u011bt\u011b\u00a0<\/strong><\/p>\n\n\n\n Z\u00e1kladem terapeutick\u00e9 platformy je v\u00edce ne\u017e 19 let hlubok\u00e9ho v\u00fdzkumu a v\u00fdvoje pod v\u011bdeck\u00fdm veden\u00edm spoluzakladatele H2 Global Group, profesora Shigeo Ohty, sv\u011btov\u011b uzn\u00e1van\u00e9ho japonsk\u00e9ho experta na v\u011bdu o molekul\u00e1rn\u00edm vod\u00edku. Platforma je chr\u00e1n\u011bna portfoliem patent\u016f a u\u017eitn\u00fdch vzor\u016f, z nich\u017e v\u011bt\u0161ina byla vyvinuta pr\u00e1v\u011b profesorem Ohtou a jeho t\u00fdmem v Japonsku. H2 Global Group je nyn\u00ed dr\u017eitelem cel\u00e9ho patentov\u00e9ho portfolia, jeho\u017e sou\u010d\u00e1st\u00ed je i patent na vyu\u017eit\u00ed molekul\u00e1rn\u00edho vod\u00edku u neurodegenerativn\u00edch onemocn\u011bn\u00ed v\u010detn\u011b demenc\u00ed, kter\u00fd je aktu\u00e1ln\u011b roz\u0161i\u0159ov\u00e1n na dal\u0161\u00ed glob\u00e1ln\u00ed trhy, v\u010detn\u011b USA.<\/p>\n\n\n\n Dce\u0159in\u00e1 spole\u010dnost H2 Medical Technologies po schv\u00e1len\u00ed St\u00e1tn\u00edm \u00fastavem pro kontrolu l\u00e9\u010div (S\u00daKL) v lednu 2026 zah\u00e1jila klinickou studii hodnot\u00edc\u00ed bezpe\u010dnost inhalace molekul\u00e1rn\u00edho vod\u00edku u pacient\u016f s m\u00edrnou kognitivn\u00ed poruchou (MCI), kter\u00e1 \u010dasto p\u0159edch\u00e1z\u00ed Alzheimerov\u011b demenci. Sou\u010dasn\u011b spole\u010dnost vstoupila do registra\u010dn\u00ed f\u00e1ze prvn\u00edho zdravotnick\u00e9ho prost\u0159edku na sv\u011bt\u011b vyu\u017e\u00edvaj\u00edc\u00edho molekul\u00e1rn\u00ed vod\u00edk. Terapeutick\u00fd potenci\u00e1l molekul\u00e1rn\u00edho vod\u00edku je podpo\u0159en v\u00edce ne\u017e 3000 v\u011bdeck\u00fdmi publikacemi a v\u00edce ne\u017e 150 studiemi na lidech, p\u0159i\u010dem\u017e po\u010d\u00e1te\u010dn\u00ed zam\u011b\u0159en\u00ed spole\u010dnosti sm\u011b\u0159uje na podporu l\u00e9\u010dby a prevence Alzheimerovy demence s mo\u017en\u00fdm roz\u0161\u00ed\u0159en\u00edm na diabetes 2. typu, z\u00e1n\u011btliv\u00e1 onemocn\u011bn\u00ed zraku a sluchu, ko\u017en\u00ed onemocn\u011bn\u00ed a podporu hojen\u00ed ran.<\/p>\n\n\n\n VR Vitalis: Certifikovan\u00fd zdravotnick\u00fd prost\u0159edek s nej\u0161ir\u0161\u00edm portfoliem na trhu\u00a0<\/strong><\/p>\n\n\n\n Druhou kl\u00ed\u010dovou komponentou platformy je VR Vitalis, certifikovan\u00fd zdravotnick\u00fd prost\u0159edek (MDR) od spole\u010dnosti VR LIFE, nasazen\u00fd ve v\u00edce ne\u017e 40 nemocnic\u00edch nap\u0159\u00ed\u010d Evropou, od fakultn\u00edch a krajsk\u00fdch nemocnic v \u010cR, Polsku a na Slovensku a\u017e po veter\u00e1nskou nemocnici v ukrajinsk\u00e9m Kremen\u010duku. Tento pokro\u010dil\u00fd nemocni\u010dn\u00ed SaaS syst\u00e9m vynik\u00e1 na trhu bezprecedentn\u00ed \u0161\u00ed\u0159\u00ed cvi\u010d\u00edc\u00edch modul\u016f pokr\u00fdvaj\u00edc\u00edch sedm kl\u00ed\u010dov\u00fdch oblast\u00ed rehabilitace: cvi\u010den\u00ed horn\u00edch a doln\u00edch kon\u010detin, zad a krku, dechov\u00e1 cvi\u010den\u00ed, kognitivn\u00ed tr\u00e9nink, jemnou motoriku a relaxaci. Jako jeden z m\u00e1la syst\u00e9m\u016f na sv\u011bt\u011b nab\u00edz\u00ed tak\u00e9 specializovan\u00e9 interaktivn\u00ed cvi\u010den\u00ed na doln\u00ed kon\u010detiny. D\u00edky flexibiln\u00edmu ovl\u00e1d\u00e1n\u00ed s ovlada\u010di i bez nich (hand tracking) je vhodn\u00fd i pro pacienty s kognitivn\u00edm deficitem \u010di omezenou motorikou. Klinick\u00e9 v\u00fdsledky potvrzuj\u00ed sn\u00ed\u017een\u00ed vn\u00edm\u00e1n\u00ed bolesti o 24\u201350 %, zv\u00fd\u0161en\u00ed motivace ke cvi\u010den\u00ed a\u017e o 60 % a mo\u017enost obsluhy t\u0159\u00ed pacient\u016f jedn\u00edm terapeutem sou\u010dasn\u011b, \u010d\u00edm\u017e z\u00e1sadn\u011b zefektiv\u0148uje p\u00e9\u010di v p\u0159et\u00ed\u017een\u00e9m zdravotnick\u00e9m syst\u00e9mu.<\/p>\n\n\n\n Rostouc\u00ed z\u00e1jem ze strany arm\u00e1dy a z\u00e1chrann\u00fdch slo\u017eek\u00a0<\/strong><\/p>\n\n\n\n Synergie molekul\u00e1rn\u00edho vod\u00edku a virtu\u00e1ln\u00ed reality otev\u00edr\u00e1 zcela nov\u00e9 mo\u017enosti nejen pro st\u00e1rnouc\u00ed populaci, ale i pro p\u0159\u00edslu\u0161n\u00edky profes\u00ed vystaven\u00fdch extr\u00e9mn\u00ed z\u00e1t\u011b\u017ei. H2 Global Group ji\u017e zaznamenala p\u0159edb\u011b\u017en\u00fd z\u00e1jem z vojensk\u00fdch n\u00e1kupn\u00edch kan\u00e1l\u016f v Evrop\u011b o vyu\u017eit\u00ed platformy pro fyzickou regeneraci po bojov\u00e9m nasazen\u00ed, podporu l\u00e9\u010dby posttraumatick\u00e9 stresov\u00e9 poruchy (PTSD) a budov\u00e1n\u00ed ment\u00e1ln\u00ed odolnosti.<\/p>\n\n\n\n Statistiky z roku 2025 ukazuj\u00ed alarmuj\u00edc\u00ed realitu: ka\u017ed\u00fd sedm\u00fd pracovn\u00edk v prvn\u00ed linii (14,3 %) trp\u00ed p\u0159\u00edznaky PTSD, 76 % kari\u00e9rn\u00edch z\u00e1chran\u00e1\u0159\u016f hl\u00e1s\u00ed chronick\u00fd stres a 45 % l\u00e9ka\u0159\u016f vykazuje zn\u00e1mky syndromu vyho\u0159en\u00ed. U voj\u00e1k\u016f vystaven\u00fdch bojov\u00e9mu nasazen\u00ed p\u0159esahuje m\u00edra PTSD 12 %, p\u0159i\u010dem\u017e tento stav je p\u0159\u00edmo spojen s masivn\u00edm oxida\u010dn\u00edm stresem a neuroz\u00e1n\u011btem.<\/p>\n\n\n\n Zat\u00edmco tradi\u010dn\u00ed psychologick\u00e1 podpora ne\u0159e\u0161\u00ed biochemick\u00e9 po\u0161kozen\u00ed bun\u011bk, platforma H2 Global Group m\u00e1 tendenci p\u016fsobit na obou front\u00e1ch. Podle dostupn\u00fdch v\u011bdeck\u00fdch studi\u00ed molekul\u00e1rn\u00ed vod\u00edk funguje jako selektivn\u00ed antioxidant, kter\u00fd podporuje ochranu nervov\u00fdch bun\u011bk a sni\u017euje hladinu stresov\u00e9ho hormonu kortizolu, zat\u00edmco VR Vitalis poskytuje okam\u017eitou psychologickou \u00falevu, reguluje dechov\u00fd vzorec a p\u0159ev\u00e1d\u00ed u\u017eivatele ze stavu stresov\u00e9 aktivace do parasympatick\u00e9ho klidu. Glob\u00e1ln\u00ed trh zdravotn\u00ed p\u00e9\u010de o veter\u00e1ny p\u0159esahuje 150 miliard dolar\u016f a jen americk\u00e9 ministerstvo pro z\u00e1le\u017eitosti veter\u00e1n\u016f alokuje na p\u0159\u00edmou l\u00e9ka\u0159skou p\u00e9\u010di v\u00edce ne\u017e 115 miliard dolar\u016f ro\u010dn\u011b.<\/p>\n\n\n\n Roz\u0161\u00ed\u0159en\u00fd p\u0159\u00edstup pro investory a strategick\u00fd potenci\u00e1l exitu\u00a0<\/strong><\/p>\n\n\n\n K urychlen\u00ed t\u00e9to du\u00e1ln\u00ed komer\u010dn\u00ed a klinick\u00e9 strategie otev\u0159ela H2 Global Group strategick\u00e9 investi\u010dn\u00ed okno p\u0159ed nadch\u00e1zej\u00edc\u00edmi klinick\u00fdmi miln\u00edky. P\u016fvodn\u00ed nab\u00eddka pro region\u00e1ln\u00ed investory v \u010cesk\u00e9 republice zaznamenala rostouc\u00ed mezin\u00e1rodn\u00ed popt\u00e1vku, co\u017e vedlo k roz\u0161\u00ed\u0159en\u00ed p\u0159\u00edstupu pro family offices, syndik\u00e1ty, ale i kvalifikovan\u00e9 individu\u00e1ln\u00ed investory, kte\u0159\u00ed hledaj\u00ed v\u010dasnou expozici v oblasti MedTech, HealthTech, longevity a dlouhodob\u00e9 p\u00e9\u010de.<\/p>\n\n\n\n Se sou\u010dasnou pre-money valuac\u00ed p\u0159ibli\u017en\u011b 80 milion\u016f USD c\u00edl\u00ed H2 Global Group na dosa\u017een\u00ed transak\u010dn\u00ed hodnoty 500 milion\u016f a\u017e 1,5 miliardy USD v horizontu t\u0159\u00ed let. Tento c\u00edl se op\u00edr\u00e1 o vlastn\u00ed du\u0161evn\u00ed vlastnictv\u00ed, rostouc\u00ed mezin\u00e1rodn\u00ed distribu\u010dn\u00ed s\u00ed\u0165 a prob\u00edhaj\u00edc\u00ed p\u0159\u00edpravy na certifikaci FDA ve Spojen\u00fdch st\u00e1tech. H2 Global Group tak sm\u011b\u0159uje ke strategick\u00e9mu exitu formou akvizice v\u00fdznamn\u00fdm glob\u00e1ln\u00edm hr\u00e1\u010dem v oblasti zdravotnick\u00fdch technologi\u00ed nebo farmacie, co\u017e p\u0159edstavuje vysoce atraktivn\u00ed hodnotovou nab\u00eddku pro st\u00e1vaj\u00edc\u00ed i budouc\u00ed partnery.<\/p>\n\n\n\n O H2 Global group<\/strong><\/p>\n\n\n\n H2 Global Group je evropsk\u00e1 technologick\u00e1 skupina se s\u00eddlem v \u010cesk\u00e9 republice, zam\u011b\u0159en\u00e1 na v\u00fdzkum, v\u00fdvoj, klinickou validaci a mezin\u00e1rodn\u00ed \u0161k\u00e1lov\u00e1n\u00ed inovativn\u00edch zdravotnick\u00fdch technologi\u00ed. Skupina se specializuje na medic\u00ednsk\u00e9 vyu\u017eit\u00ed molekul\u00e1rn\u00edho vod\u00edku a na propojov\u00e1n\u00ed chytr\u00e9ho kapit\u00e1lu s inovacemi v oblastech MedTech, HealthTech, longevity a dlouhodob\u00e9 p\u00e9\u010de. Spojen\u00edm pr\u016flomov\u00e9 japonsk\u00e9 biochemick\u00e9 v\u011bdy s digit\u00e1ln\u00edmi technologiemi, jako je virtu\u00e1ln\u00ed realita, vytv\u00e1\u0159\u00ed komplexn\u00ed \u0159e\u0161en\u00ed pro kognitivn\u00ed zdrav\u00ed, regeneraci a zvl\u00e1d\u00e1n\u00ed chronick\u00e9ho stresu, od dom\u00e1cnost\u00ed p\u0159es domovy senior\u016f, rehabilita\u010dn\u00ed centra a nemocnice a\u017e po z\u00e1chrann\u00e9 slo\u017eky a arm\u00e1du.<\/p>\n\n\n\n www.H2global.group \/ www.H2invest.cz \/ www.H2medical.com<\/a><\/p>\n\n\n\n Zdroj: H2 Global Group<\/p>\n\n\n\n \u010cTK Connect is releasing an image attachment with this report, which is available at https:\/\/www.protext.cz<\/a>.<\/p>\n\n\n\n Zdroj: https:\/\/www.protext.cz\/zpravy\/armada-a-zachranne-slozky-v-hledacku-evropska-medtech-inovace-s-japonskymi-koreny-vysila-silny-signal-investorum-a-partnerum\/57113<\/a><\/p>","protected":false},"excerpt":{"rendered":" The valuation growth of VR LIFE, strong clinical traction, and the upcoming entry into the US market are strengthening the strategy of H2 Global Group. Furthermore, the innovative platform, which combines Japanese research on molecular hydrogen and virtual reality, is seeing growing interest from the military and the integrated rescue system. European MedTech innovator H2… Arm\u00e1da a z\u00e1chrann\u00e9 slo\u017eky v hled\u00e1\u010dku: Evropsk\u00e1 MedTech inovace s japonsk\u00fdmi ko\u0159eny vys\u00edl\u00e1 siln\u00fd sign\u00e1l investor\u016fm a partner\u016fm<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":1240,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1239","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts\/1239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/comments?post=1239"}],"version-history":[{"count":1,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts\/1239\/revisions"}],"predecessor-version":[{"id":1241,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts\/1239\/revisions\/1241"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/media\/1240"}],"wp:attachment":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/media?parent=1239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/categories?post=1239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/tags?post=1239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}